CBX1 and polycystic kidney disease: For compounds 7, 12e and 12f, the IC50 values were calculated, and for 12f, they were lower than those of CBX (IC50 = 2.7 μM versus IC50 = 7.1 μM); moreover, the most potent products 12e and 12f, tested during a 3-week period at 10 μM and 3 μM, respectively, in a cell culture model of polycystic kidney disease, reduced the size of cysts by about 13%, thus confirming the therapeutic potential of Panx1 blockers on cystogenesis.